|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009
Decision Resources, Inc., Oct 2009, Pages: 40
The third quarter of 2009 saw a heated debate in the United States over healthcare reform, the publication of a report on a European investigation of the pharmaceutical industry, the election of new governments in Japan and Germany, and new initiatives by governments in other countries to control their national pharmaceutical spending. Faced with declining revenues and increasing expenditures, healthcare payers in all markets are exerting increasing pressure on the pharmaceutical industry to cut costs and deliver genuine innovation.
Questions Answered in This Report:
In the United States, the Democrats are committed to passing healthcare reform legislation by the end of the year.
- What difficulties have lawmakers encountered in drafting legislation?
- What are the recent trends in health insurance coverage in the United States?
- What deal has the U.S. government struck with the pharmaceutical industry?
The French government is looking to cut $2 billion from the national healthcare budget in 2010.
- How much does the government hope to save by cutting prices, reducing the reimbursement rate of certain drugs, and stimulating greater use of generics?
- What impact are new voluntary physician contracts likely to have on the French pharmaceutical market?
Spending on prescription drugs by the German statutory health insurance system grew by 5.3% in 2008.
- How did spending and pricing trends compare for generic and branded drugs?
- What changes would some health insurance funds like the government to make to controls on pharmaceutical coverage?
- What new restriction has the government introduced on coverage for certain cancers?
The economic downturn is beginning to have an impact on the U.K. healthcare system.
- What is the effect on pharmaceutical budgets?
- How have recent price cuts and exchange rate movements altered parallel trade patterns and contributed to shortages of certain drugs?
The Japanese pricing and reimbursement environment faces the prospect of significant changes in the coming years.
- How is the new government likely to respond to industry proposals for a price maintenance system?
- How will generics feature in future government healthcare policy?
- What are the implications of a recently confirmed restriction on access to drugs not yet approved in Japan?
Scope
- Issues affecting the pharmaceutical industry in the United States: healthcare reform; health insurance trends; drug benefit trends; managed care executives’ views on comparative effectiveness research; regulatory pathway for biosimilars.
- Issues affecting the pharmaceutical industry in Europe: market trends; generic drug use; proposed prescribing and reimbursement restrictions; shifting patterns of parallel trade; impact of the economic downturn on the pharmaceutical market; access to medicines.
- Issues affecting the pharmaceutical industry in Japan: prospects for the introduction of a price maintenance system; government policy on generics; reimbursement of drugs not yet approved in Japan.
Customers who bought this item also bought
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
Pharmaceutical Pricing, Reimbursement, and Market Access in Poland, Romania and Ukraine
Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs
Pharmaceutical Pricing, Reimbursement, and Market Access in Turkey
Pharmaceutical Pricing, Reimbursement, and Market Access News in the First Quarter of 2011
Pharmaceutical Pricing, Reimbursement and Market Access News in the First Quarter of 2010
The Pricing and Reimbursement Environment for Respiratory Disease Therapies
Obama's Healthcare Reform Bill and its Impact on the U.S. Healthcare Market
Pharmaceutical Pricing and Reimbursement in Canada
Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
|
|
|
|
